Background {#Sec1}
==========

The metabolic syndrome (MetS) is a constellation of cardiovascular risk factors centered around obesity, abnormal glucose metabolism, hypertension and atherogenic dyslipidemia \[[@CR1], [@CR2]\].

These risk factors tend to cluster together in patients, and when they do, they substantially increase the risk for the development of cardiovascular disease \[[@CR2]\]. The prevalence of the MetS is increasing, coincident with increasing levels of obesity related to sedentary lifestyles and poor nutrition habits \[[@CR3]--[@CR6]\].

The association of the MetS with increased risk of adverse cardiovascular outcomes, morbidity and mortality is well established \[[@CR7]--[@CR13]\]. However, controversy remains regarding independent character of this association as well as regarding the additional value of the MetS in the risk estimation on top of its individual components. Furthermore, recent studies showed that MetS is associated with an increased risk of cardiovascular mortality and re-infarction in patients with cardiovascular disease \[[@CR14], [@CR15]\], however, these studies are mostly limited to patients after a recent acute coronary syndrome (ACS) or after revascularization, and there is limited data regarding patients with stable coronary disease without revascularization procedures \[[@CR16]\]. Furthermore, to date the follow-up period in the majority of studies exploring the association of MetS and mortality is less than 3 years \[[@CR16]--[@CR21]\] and these studies have predominantly explored cardiovascular mortality and not all-cause mortality as their primary outcome \[[@CR16]--[@CR21]\].

Thus, limited data exist regarding the association between the presence of MetS and long-term all-cause mortality among patients with stable coronary artery disease (CAD), especially among those who have not undergone prior coronary revascularization or recent ACS. It is unclear whether this association is independent following adjustment for other comorbidities and clinical characteristics. Furthermore, the principle definitions of MetS have not been compared in large cohorts of patients with stable CAD.

Accordingly, the aims of the present study were to: (1) determine the independent association of MetS as defined by the National Cholesterol Education Program (NCEP) vs. the International Diabetes Federation (IDF) criteria with 20-year all-cause mortality outcome; (2) evaluate the heterogeneity of the association between MetS and mortality in important subgroups of patients.

Methods {#Sec2}
=======

Study population {#Sec3}
----------------

The present study population comprised patients who were screened for participation in the Bezafibrate Infarction Prevention (BIP) trial between February 1990 and October 1992 and enrolled in the BIP Registry. The design and rationale of the BIP Registry and study were published previously \[[@CR22], [@CR23]\]. Of the 15,524 screened patients, only 3090 (20%) proceeded to be randomized in the prospective interventional 6-year BIP study that compared Bezafibrate to placebo. As the intervention period ended more than 15 years ago we decided to include these patients in our analysis cohort.

Briefly, BIP Registry included 15,524 patients aged 40--74 years with stable CAD fulfilling the following inclusion criteria: (1) documented myocardial infarction (MI) in the previous 5 years, (2) symptomatic stable angina pectoris and either a positive myocardial ischemia by radio-nuclear-scintigraphy, or ≥60% stenosis of 1 of the major coronary arteries, demonstrated by coronary angiography, or (3) documented percutaneous transluminal coronary angioplasty (PTCA) or coronary artery bypass grafting (CABG) operation in the preceding 6 months. Exclusion criteria included: diabetes mellitus requiring the use of insulin, severe heart failure, unstable angina, hepatic or renal failure, and current use of lipid-modifying drugs.

All medical examination and biochemical blood-tests, historical medical data, as well as data on drug therapy were prospectively recorded and all vital signs measured.

After exclusion of those patients with missing laboratory values the final data set for the current study comprised of 15,413 patients. Median follow up duration was 20 ± 5 years.

The study was approved by the institute's internal review board and was performed according to the principles expressed in the Declaration of Helsinki and the ethics policy of the institute.

Metabolic syndrome definitions {#Sec4}
------------------------------

Currently, there are two major definitions for MetS: the International Diabetes Federation (IDF) \[[@CR24], [@CR25]\] and National Cholesterol Education Program--Third Adult Treatment Panel (NCEP) \[[@CR26]\]. Accordingly, study patients were categorized by the presence or lack of MetS by the two separate definitions.

### Diagnosis criteria {#Sec5}

Patients who presented with three or more of the following five risk factors were defined as having MetS according to the NCEP:Central obesity defined as waist circumference greater than established ethnicity specific values. Since the data regarding waist circumference were not available, for purposes of this analysis we used the accepted body mass index (BMI) above 30 as a criterion for classifying patients as obese \[[@CR25], [@CR27]\].Low high-density lipoprotein (HDL) \<50 mg/dL among women, and \<40 mg/dL among men.Elevated fasting plasma triglycerides (TG) ≥150 mg/dL, or specific treatment for this lipid abnormality.Elevated systolic blood pressure ≥130 mm Hg, or diastolic value ≥85 mm Hg, or treatment of previously diagnosed hypertension.Elevated fasting plasma glucose (FPG) ≥100 mg/dL or previously diagnosed diabetes mellitus.

The definition of the MetS according to the IDF has some modifications as it requires central obesity as an obligatory criterion, and two or more of the other criteria as detailed above. Central obesity can be substituted by BMI \>30 \[[@CR25], [@CR27], [@CR28]\].

Patients were defined as diabetics based on their medical record diagnosis as prospectively coded at study entry. The same method was applied to the definitions of hypertension, smoking status and other elements of medical history. Patients with diabetes were considered in this analysis as having impaired fasting glucose even if their point measurement of FPG was below 100 mg/dL.

### Laboratory methods {#Sec6}

Blood samples were drawn after at least 12 h of fasting. Cooled samples, collected in the 18 participating centers using standard equipment and procedures, were transferred to the study's central laboratory. All analyses were performed on a Boehringer Hitachi 704 random access analyzer using Boehringer diagnostic kits. Detailed data on laboratory methods were given in a previous report \[[@CR29]\].

Primary end point {#Sec7}
-----------------

The primary end point of this study was all-cause mortality. Mortality data was obtained by matching the patient's identification numbers with their vital status available in the National Population Registry of Israel. Each match record was checked for correct identification by matching the date of birth coded during survey enrollment with the date of birth available from the national registry. Patients with missing values or inconsistent matching were excluded from the present analysis (n = 111).

Statistical analysis {#Sec8}
--------------------

Continuous variables are expressed as mean ± standard deviation (SD), and categorical data are summarized as percentages. The clinical characteristics of the patients at baseline by presence of the MetS were compared with the use of the unpaired t test for continuous variables or Mann--Whitney as appropriate, and the Chi square test for categorical variables.

The Kaplan--Meier method was used to calculate cumulative survival curves for patients with and without MetS and the curves were compared using a Log rank test.

Multivariate Cox proportional hazard regression modeling was used to assess the independent effect of the MetS on the primary end point of all-cause mortality. The following covariates were introduced using the best subset method, following a univariate analysis of all relevant variables: age, gender, smoking status, creatinine concentration, diagnosis of diabetes mellitus (DM), hypertension, heart failure NYHA \>2, previous MI or past cerebrovascular accident (CVA). We additionally performed multivariate analysis as described above and included medication (anti-platelets, nitrates, calcium channel blockers, beta blockers and diuretics) as additional covariates.

Proportionality of hazard assumption was verified using Schoenfeld residuals and the log minus log (LML) method. We additionally performed a sensitivity analysis excluding patients randomized to the BIP randomized study (n = 3090).

In order to further explore the independent risk associated with the presence of MetS in pre-specified patient subgroups we performed interaction term analysis by the introduction of an MetS-by-risk-subgroup interaction-term to the multivariate age adjusted Cox model (MetS by age interaction was not further adjusted). The following pre-specified subgroups were explored: age ≥65 years, gender, prior MI, renal dysfunction \[serum creatinine \>1.5 mg/dL\], and New York Heart Association (NYHA) class \>2. Interaction analysis is graphically presented in the form of a Forest plot.

Furthermore, in order to confirm our findings, an additional sensitivity analysis was performed, in which the waist circumference\\BMI criteria were excluded, and the diagnosis of MetS was made if patients had two out of the four remaining criteria.

Statistical significance was declared for a two-sided p \< 0.05. The statistical analysis was performed with IBM SPSS version 20.0 (Chicago, IL, USA) and SAS version 9.2 (SAS institute Inc.) statistical software.

Results {#Sec9}
=======

Based on the criteria of the IDF 2122 (14%) patients had MetS, compared to 13,291 (86%) patients without the MetS, whereas based on the NCEP criteria 7446 (48%) patients had MetS, and 7967 (52%) were considered without. Baseline characteristics of patients with and without MetS according to both definitions are summarized in Table [1](#Tab1){ref-type="table"}.Table 1Baseline characteristics of the study population by the two metabolic syndrome definitionsMetabolic IDF definition*P* valueMetabolic NCEP definition*P* valueNo (n = 13,291)Yes (n = 2122)No (n = 7967)Yes (n = 7446)Age (years)^a^60 ± 759 ± 7\<0.00160 ± 760 ± 70.29Male gender10,910 (82%)1540 (73%)\<0.0016600 (83%)5850 (78%)\<0.001Active smoker1485 (11%)276 (13%)\<0.001832 (47%)929 (53%)\<0.001HTN4197 (32%)948 (45%)\<0.0012197 (27%)2948 (40%)\<0.001DM2355 (18%)604 (29%)\<0.001784 (10%)2175 (30%)\<0.001COPD382 (3%)70 (3%)0.27238 (3%)214 (3%)0.85Past MI9611 (72%)1519 (72%)0.915754 (72%)5376 (72%)0.92Past CVA236 (1.8%)33 (1.6%)0.47131 (1.6%)138 (1.9%)0.26NYHA class \>2753 (5%)185 (9%)\<0.001409 (5%)491 (6.8%)\<0.001Laboratory values (mg/dL) Creat^a^1.15 ± 0.21.11 ± 0.2\<0.0011.15 ± 0.21.14 ± 0.20.02 CHO^a^224 ± 39228 ± 42\<0.001212 ± 37228 ± 41\<0.001 LDL^a^155 ± 34155 ± 370.73154 ± 33156 ± 36\<0.001Medication Bezafibrate1369 (10%)193 (9%)0.10784 (10%)778 (10%)0.22 Placebo1347 (10%)210 (10%)0.68760 (9.5%)797 (11%)0.02 Beta-blockers4527 (34%)873 (41%)\<0.0012484 (31%)2916 (39%)\<0.001 Nitrates6568 (49%)1150 (54%)\<0.0013856 (48%)3861 (51%)\<0.01 CCB6555 (49%)1160 (54%)\<0.0013904 (49%)3810 (51%)\<0.01 Diuretics1926 (14%)449 (21%)\<0.0011018 (13%)1356 (18%)\<0.001 Anti-platelets agents7934 (59%)1136 (53%)\<0.0014867 (61%)4203 (56%)\<0.001Components of the metabolic syndrome FPG \>100 mg/dL5805 (44%)1412 (67%)\<0.0011873 (23%)5347 (72%)\<0.001 Low HDL^b^9155 (73%)1858 (90%)\<0.0014065 (56%)6948 (94%)\<0.001 TG \>150 mg/dL5226 (40%)1297 (61%)\<0.0011198 (15%)5325 (72%)\<0.001 BMI \>30 kg/m^2^340 (2.6%)2122 (100%)\<0.001340 (4%)2122 (28%)\<0.001 Elevated BP^c^8978 (68%)1761 (83%)\<0.0014329 (54%)6410 (86%)\<0.001*BMI* body mass index; *BP* blood pressure; *CHO* total cholesterol; *COPD* chronic obstructive pulmonary disease; *Creat* creatinine; *CVA* cerebral vascular accident; *DM* diabetes mellitus; *FPG* fasting plasma glucose; *HDL* high-density lipoprotein; *HTN* hypertension; *IDF* International Diabetes Federation; *LDL* low density lipoprotein; *MI* myocardial infarction; *NCEP* National Cholesterol Educational Program; *NYHA* New York Heart Association; *TG* triglycerides^a^Continuous variables are reported as mean ± standard deviation if normally distributed; otherwise, as median with 25th--75th range. Categorical variables are reported as numbers (%)^b^Low HDL defined as HDL \<40 mg/dL in males and HDL \<50 mg/dL in females^c^Systolic blood-pressure \>130 mmHg or/and diastolic blood-pressure \>85 mmHg

As expected, patients with MetS had an adverse clinical and biochemical profile, including higher incidence of diabetes, hypertension, hypercholesterolemia, and NYHA class \>2. According to the IDF definition, patients with the MetS were slightly younger, with a male predominance, and had slightly lower serum creatinine concentration compared to patients without MetS (Table [1](#Tab1){ref-type="table"}).

Prevalence of past CVA, and chronic obstructive lung disease (COPD) were similar. Low-density lipoprotein (LDL) levels and history of past MI were similar when MetS was defined by IDF criteria. When MetS was defined according to the NCEP criteria, past MI rates was similar between groups, however, LDL levels were higher in the MetS group vs. those without MetS (156 ± 36 vs. 154 ± 33, p \< 0.001).

Patients with the MetS were significantly more likely to receive beta-blockers, diuretics, calcium channel blockers and nitrates, and less likely to receive antiplatelet therapy (Table [1](#Tab1){ref-type="table"}).

We further compared the individual components of MetS defined by the NCEP vs. the IDF criteria (Additional file [1](#MOESM1){ref-type="media"}: Table S1). Patients categorized according to the NCEP definition were more likely to have other metabolic components (hypertension, IFG, hypertriglyceridemia and low HDL) with the exception of BMI \>30 that was present in only 28% of the NCEP group vs. 100% of the IDF group (all p value \< 0.001).

Long-term mortality by the presence of MetS {#Sec10}
-------------------------------------------

Kaplan--Meier survival analysis showed that at 20 years of follow-up all-cause mortality probability was significantly higher among patients with MetS vs. those without MetS (Fig. [1](#Fig1){ref-type="fig"}). When defined by the IDF criteria the respective cumulative mortality probability at 20 years were 1429 (67%) and 8095 (61%) (p \< 0.001 for the overall comparison during follow-up; Fig. [1](#Fig1){ref-type="fig"}a), and when defined by the NCEP criteria the respective rates were 4987 (67%) and 4329 (54%) (p \< 0.001 for the overall comparison during follow-up; Fig. [1](#Fig1){ref-type="fig"}b). Notably, separation in event rates between MetS and non-MetS patients appeared after approximately one year and was sustained thereafter.Fig. 1Kaplan-Meier 20-year survival estimates for the entire cohort. **a** Survival estimates according to the presence or absence of the metabolic syndrome according to the IDF definition. **b** Survival estimates according to the presence or absence of metabolic syndrome according to the NCEP definition. *Cre* creatinine; *DM* diabetes mellitus; *IDF* International Diabetes Federation; *LDL* low density lipoprotein; *MetS* metabolic syndrome; *MI* myocardial infarction; *NCEP* National Cholesterol Educational Program

Consistently, multivariate adjusted for: age, gender, smoking status and major comorbidities (Creatinine \>1.5 mg/dL, DM, HTN, past MI, previous CVA and NYHA \>2), MetS defined by the NCEP was associated with a significant 21% independent increased mortality risk (HR 1.21; 95% CI 1.13--1.29; Table [2](#Tab2){ref-type="table"}a) whereas MetS defined by the IDF, was similarly independently associated with a 17% increased all-cause mortality risk (HR 1.17; 95% CI 1.07--1.28; Table [2](#Tab2){ref-type="table"}b). Consistent results were obtained when patients randomized to the interventional BIP trial (n = 3090) were excluded or when medications were adjusted for. The mortality risk associated with MetS was similar when BMI was excluded, and patients were defined based only on two out of remaining four criteria.Table 2Independent all-cause mortality risk predictors in patients with stable CAD using the (a) NCEP and (b) IDF MetS definitionAdjusted HR95% CI for upper*P* value(a) Hazard ration among the NCEP metabolic groupMetabolic NCEP1.211.14--1.29\<0.001 Age \>65 years1.081.07--1.08\<0.001 Male gender1.191.09--1.31\<0.001 Creatinine \>1.5 mg/dL1.591.38--1.84\<0.001 Diabetes mellitus1.611.49--1.74\<0.001 Hypertension1.081.01--1.150.01 Past MI1.411.31--1.52\<0.001 Previous CVA1.070.83--1.390.59 NYHA \>21.251.10--1.43\<0.001 Active smoker1.571.43--1.71\<0.001(b) Hazard ration among the IDF metabolic groupMetabolic IDF1.171.07--1.28\<0.001 Age \>65 years1.081.08--1.09\<0.001 Male gender1.171.06--1.29\<0.001 Creatinine \>1.5 mg/dL1.601.38--1.84\<0.001 Diabetes mellitus1.681.56--1.81\<0.001 Hypertension1.101.04--1.180.003 Past MI1.411.31--1.52\<0.001 Previous CVA1.100.85--1.420.48 NYHA \>21.231.07--1.410.003 Active smoker1.571.43--1.72\<0.001Both models further adjusted for: hypertension, smoking status, and severe heart failure (NYHA \>2)*CI* 95% confidence interval; *CVA* cerebral-vascular accident; *HR* hazard ratio; *MI* myocardial infarction; *NCEP* National Cholesterol Education Program; *IDF* International Diabetes Federation; *NYHA* New York Heart Association

Increased serum creatinine, the presence of diabetes mellitus, current smoking and a history of myocardial infarction were additional independent predictors of all-cause mortality (Table [2](#Tab2){ref-type="table"}a, b).

Subgroup analysis {#Sec11}
-----------------

We further explored the independent association between the presence of MetS and long-term mortality in predefined subgroups of patients (Fig. [2](#Fig2){ref-type="fig"}). This analysis showed that the mortality risk was increased by 15--25% across all major groups when both definitions of MetS were used, with the exception of patients with creatinine concentration \>1.5 mg/dL (p value of interaction p = 0.04) and those 65 years old or older, when NCEP definition was used (p value for interaction = 0.003; Fig. [2](#Fig2){ref-type="fig"}a, b).Fig. 2Mortality risk associated with metabolic syndrome presence according to the IDF (**a**) and NCEP definitions (**b**) in pre-specified subgroups. Both models further adjusted for: hypertension, smoking status, and severe heart failure (NYHA \>2). *Cre* creatinine; *DM* diabetes mellitus; *IDF* International Diabetes Federation; *LDL* low density lipoprotein; *MetS* metabolic syndrome; *MI* myocardial infarction; *NCEP* National Cholesterol Educational Program

Discussion {#Sec12}
==========

The primary findings of our study are: (1) MetS is associated with approximately 20% greater all-cause mortality risk at 20-year of follow-up; the risk is independent of other important predictors of adverse outcomes; (2) The two leading definitions of MetS, respectively IDF and NCEP criteria, have similar long-term prognostic implications despite the inclusion of a much greater number of patients according to the NCEP definition; (3) the mortality risk associated with MetS is consistent in most patient subgroups, with the possible exception of those with renal dysfunction and less pronounced in patients aged 65 years or older.

A number of prior large-scale studies demonstrated the long-term prognostic significance of every single metabolic component of the MetS \[[@CR15], [@CR30]--[@CR33]\], whereas controversy remains regarding additional value of the MetS in the risk estimation on top of its individual components \[[@CR28], [@CR34]--[@CR39]\].

Although earlier studies tend to show a significant association between MetS and all-cause mortality especially among middle-aged individuals similar to our cohort, \[[@CR10], [@CR40]--[@CR42]\] they were shorter in duration \[[@CR17], [@CR20], [@CR43], [@CR44]\], had smaller samples \[[@CR45]--[@CR47]\], had cardiovascular mortality as their primary outcome and comprised mostly of patients after an intervention \[[@CR17], [@CR20], [@CR43]--[@CR47]\]. In studies by Marso et al. and Miller et al. patients with acute coronary syndrome were enrolled, rather than patients with a stable coronary disease \[[@CR32], [@CR33]\].

On the other hand, more recent studies, who enrolled patients with ACS were unable to demonstrate such an association in coronary patients after ACS or revascularization. \[[@CR48], [@CR49]\].

The largest meta-analysis that included near one million patients (total n = 951,083) concluded that the MetS is associated with a twofold increase in cardiovascular outcomes and a 1.5-fold increase in all-cause mortality rates \[[@CR42]\]. Nevertheless, most subjects included in this analysis had no overt cardiovascular disease.

One recent large study by van Herpt et al. has shown that MetS increased the all-cause mortality in univariate analysis, yet was unable to find any significant associations of MetS with all-cause mortality after adjustment for age, gender and comorbidities. \[[@CR39]\].

Additionally, previous studies were limited by their small size and relatively modest follow-up period, which was mostly less than 3 years in the majority of studies concerning the MetS and mortality. \[[@CR16]--[@CR21]\] Furthermore these studies have explored the cardiovascular mortality rather than all-cause mortality as their primary outcome. \[[@CR16]--[@CR21]\].

Hence the enrollment for this study took place between the years 1990 and 1992, the majority of the patients didn't undergo revascularization at the time of their enrollment. While most studies that evaluated patients after a recent acute coronary syndrome \[[@CR14], [@CR15], [@CR30]\] or after coronary revascularization \[[@CR16]--[@CR21]\] failed to show a significant effects of MetS on mortality among patients with stable coronary artery disease and without revascularization, our study did find a significant association with all-cause mortality.

To the best of our knowledge, our study is the largest and presents the longest follow-up period of patients with stable CAD demonstrating an independent association of MetS with all-cause mortality.

Despite the significant numeric difference, and the significant difference of their metabolic components, both MetS groups (IDF and NCEP definitions), had almost a similar effect on the 20-year all-cause mortality outcome, regardless of the definition employed.

Notably, the number of patients with MetS according to NCEP criteria was significantly larger than the number obtained when the IDF criteria were utilized (7446 vs. 2122). This difference is due to the obligatory inclusion of the central obesity as a required according to the IDF criteria, in addition to the two or more of the remaining 4 criteria detailed above. In contrast, the NCEP does not present such an obligatory requirement and is based on the presence of any three criteria. This leads to the fact that all IDF patients are also included in the NCEP group.

Despite the fact that the presence of the MetS possesses a definite predictive value, the view of this metabolic cluster as a prognostic tool only will be too simplistic. MetS is a widely accepted concept regarding a biological condition based on the complex and interrelated pathophysiological mechanisms starting from excess central adiposity and insulin resistance. MetS identifies additional important residual vascular risk mainly associated with insulin resistance, atherogenic dyslipidemia, non-alcoholic fatty liver and type 2 diabetes development. Therefore, the MetS could be a useful additional contributor in estimation of global cardiovascular risk beyond its components and other standard risk factors like age, high LDL-C, etc. \[[@CR50]--[@CR55]\].

Moreover, the concept that the metabolic syndrome is a consequence of obesity and insulin resistance, provides a useful "life-style changes" approach for prevention and treatment: caloric restriction, weight-loss and increased physical activity within cardiac rehabilitation programs for patients with CAD.

Limitations {#Sec13}
===========

Our study has a number of limitations. First, it is a retrospective study that enrolled patients during a period where different treatments were used for controlling blood glucose, hyperlipidemia and hypertension, thus our results warrant validation in more contemporary populations. Second, not all confounders can be accounted for nor were all possible variables measured at enrolment. Third, we have no data regarding clinical events and clinical management after the screening period. Finally, our data lacks waist circumference assessment which is important element of the definition of central obesity as a component of the MetS. However, we replaced this criteria with the BMI \>30 according to the consensus of the IDF and NCEP. Furthermore, when we excluded the BMI criteria, and set the diagnosis of MetS as the presence of two out the four remaining criteria, similar results were obtained.

Conclusions {#Sec14}
===========

Metabolic syndrome is independently associated with increased 20-year mortality in patients with stable coronary artery disease. The excess of the very long-term mortality risk was consistent regardless of the MetS definition employed and similar across most population subgroups, yet less pronounced in patients of 65 year or older and absent in patients with renal failure.

Additional file {#Sec15}
===============

**Additional file 1: Table S1.** Differences between the MetS definitions in terms of their individual components.
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